Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data

Table 4 Logistic regression analyses for neuropathy occurrence in 2016 and 2017 Health Insurance Review and Assessment national patient sample data

			Propensity score-matched1
	OR	95%CI	OR	95%CI
2016
Statin use	1.22	1.07-1.38	1.22	1.08-1.38
Metformin use	0.73	0.61-0.87	0.30	0.21-0.42
Statin + metformin use	0.78	0.62-1.01	0.85	0.61-1.19
2017
Statin use	1.13	1.00-1.29	1.17	1.03-1.33
Metformin use	0.84	0.71-1.02	0.44	0.32-0.60
Statin + metformin use	0.92	0.70-1.21	0.95	0.66-1.38

¹Propensity score-matching was performed by including baseline age, gender, and comorbidities (myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular accident or transient ischemic attack, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, liver disease, diabetes mellitus, hemiplegia, moderate to severe chronic kidney disease, solid tumor, leukemia, lymphoma, AIDS). OR: Odds ratio; CI: Confidence interval.